Molecular detection of B-cell neoplasms by specific DNA methylation biomarkers

Michael X. Wang, Huan You Wang, Xiaohui Zhao, Nalluri Srilatha, Dali Zheng, Huidong Shi, Jie Ning, Deiter J. Duff, Kristen H. Taylor, Barbara A. Gruner, Charles W. Caldwell

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

A novel, easy to perform PCR-based method employing specific DNA methylation biomarkers to detect Bcell neoplasms in a variety of B-cell lines and B lymphoblastic leukemia (B-ALL) patient specimens has been developed. This method detects as few as 5 B-ALL cells, or 1 B-ALL cell in 1,000,000 normal background blood cells using a single marker, DLC-1 gene CpG island (CGI) methylation. By adding two additional markers PCDHGA12 and RPIB9, over 80% of B-ALL cases were detected in patients' bone marrow and/or peripheral blood specimens. We have traced clinical B-ALL cases up to 10 years retrospectively and the DLC-1 methylation is correlated with patient clinical status. Thus, this epigenetic-based molecular method demonstrates its potential use in the diagnosis of B-cell neoplasia, in addition to traditional approach such as clinical features, morphology, immunophenotype, and genetic analysis.

Original languageEnglish (US)
Pages (from-to)265-279
Number of pages15
JournalInternational Journal of Clinical and Experimental Pathology
Volume3
Issue number3
StatePublished - Sep 1 2010

Fingerprint

Neoplasm DNA
DNA Methylation
B-Lymphocytes
Biomarkers
Methylation
CpG Islands
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Epigenomics
Blood Cells
Neoplasms
Bone Marrow
Cell Line
Polymerase Chain Reaction
Genes

Keywords

  • B lymphoblastic leukemia
  • DNA methylation biomarker
  • Mature B-cell neoplasms

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Histology

Cite this

Wang, M. X., Wang, H. Y., Zhao, X., Srilatha, N., Zheng, D., Shi, H., ... Caldwell, C. W. (2010). Molecular detection of B-cell neoplasms by specific DNA methylation biomarkers. International Journal of Clinical and Experimental Pathology, 3(3), 265-279.

Molecular detection of B-cell neoplasms by specific DNA methylation biomarkers. / Wang, Michael X.; Wang, Huan You; Zhao, Xiaohui; Srilatha, Nalluri; Zheng, Dali; Shi, Huidong; Ning, Jie; Duff, Deiter J.; Taylor, Kristen H.; Gruner, Barbara A.; Caldwell, Charles W.

In: International Journal of Clinical and Experimental Pathology, Vol. 3, No. 3, 01.09.2010, p. 265-279.

Research output: Contribution to journalArticle

Wang, MX, Wang, HY, Zhao, X, Srilatha, N, Zheng, D, Shi, H, Ning, J, Duff, DJ, Taylor, KH, Gruner, BA & Caldwell, CW 2010, 'Molecular detection of B-cell neoplasms by specific DNA methylation biomarkers', International Journal of Clinical and Experimental Pathology, vol. 3, no. 3, pp. 265-279.
Wang, Michael X. ; Wang, Huan You ; Zhao, Xiaohui ; Srilatha, Nalluri ; Zheng, Dali ; Shi, Huidong ; Ning, Jie ; Duff, Deiter J. ; Taylor, Kristen H. ; Gruner, Barbara A. ; Caldwell, Charles W. / Molecular detection of B-cell neoplasms by specific DNA methylation biomarkers. In: International Journal of Clinical and Experimental Pathology. 2010 ; Vol. 3, No. 3. pp. 265-279.
@article{45b05596fb8c4177a8b7ad1846c5af66,
title = "Molecular detection of B-cell neoplasms by specific DNA methylation biomarkers",
abstract = "A novel, easy to perform PCR-based method employing specific DNA methylation biomarkers to detect Bcell neoplasms in a variety of B-cell lines and B lymphoblastic leukemia (B-ALL) patient specimens has been developed. This method detects as few as 5 B-ALL cells, or 1 B-ALL cell in 1,000,000 normal background blood cells using a single marker, DLC-1 gene CpG island (CGI) methylation. By adding two additional markers PCDHGA12 and RPIB9, over 80{\%} of B-ALL cases were detected in patients' bone marrow and/or peripheral blood specimens. We have traced clinical B-ALL cases up to 10 years retrospectively and the DLC-1 methylation is correlated with patient clinical status. Thus, this epigenetic-based molecular method demonstrates its potential use in the diagnosis of B-cell neoplasia, in addition to traditional approach such as clinical features, morphology, immunophenotype, and genetic analysis.",
keywords = "B lymphoblastic leukemia, DNA methylation biomarker, Mature B-cell neoplasms",
author = "Wang, {Michael X.} and Wang, {Huan You} and Xiaohui Zhao and Nalluri Srilatha and Dali Zheng and Huidong Shi and Jie Ning and Duff, {Deiter J.} and Taylor, {Kristen H.} and Gruner, {Barbara A.} and Caldwell, {Charles W.}",
year = "2010",
month = "9",
day = "1",
language = "English (US)",
volume = "3",
pages = "265--279",
journal = "International Journal of Clinical and Experimental Pathology",
issn = "1936-2625",
publisher = "e-Century Publishing Corporation",
number = "3",

}

TY - JOUR

T1 - Molecular detection of B-cell neoplasms by specific DNA methylation biomarkers

AU - Wang, Michael X.

AU - Wang, Huan You

AU - Zhao, Xiaohui

AU - Srilatha, Nalluri

AU - Zheng, Dali

AU - Shi, Huidong

AU - Ning, Jie

AU - Duff, Deiter J.

AU - Taylor, Kristen H.

AU - Gruner, Barbara A.

AU - Caldwell, Charles W.

PY - 2010/9/1

Y1 - 2010/9/1

N2 - A novel, easy to perform PCR-based method employing specific DNA methylation biomarkers to detect Bcell neoplasms in a variety of B-cell lines and B lymphoblastic leukemia (B-ALL) patient specimens has been developed. This method detects as few as 5 B-ALL cells, or 1 B-ALL cell in 1,000,000 normal background blood cells using a single marker, DLC-1 gene CpG island (CGI) methylation. By adding two additional markers PCDHGA12 and RPIB9, over 80% of B-ALL cases were detected in patients' bone marrow and/or peripheral blood specimens. We have traced clinical B-ALL cases up to 10 years retrospectively and the DLC-1 methylation is correlated with patient clinical status. Thus, this epigenetic-based molecular method demonstrates its potential use in the diagnosis of B-cell neoplasia, in addition to traditional approach such as clinical features, morphology, immunophenotype, and genetic analysis.

AB - A novel, easy to perform PCR-based method employing specific DNA methylation biomarkers to detect Bcell neoplasms in a variety of B-cell lines and B lymphoblastic leukemia (B-ALL) patient specimens has been developed. This method detects as few as 5 B-ALL cells, or 1 B-ALL cell in 1,000,000 normal background blood cells using a single marker, DLC-1 gene CpG island (CGI) methylation. By adding two additional markers PCDHGA12 and RPIB9, over 80% of B-ALL cases were detected in patients' bone marrow and/or peripheral blood specimens. We have traced clinical B-ALL cases up to 10 years retrospectively and the DLC-1 methylation is correlated with patient clinical status. Thus, this epigenetic-based molecular method demonstrates its potential use in the diagnosis of B-cell neoplasia, in addition to traditional approach such as clinical features, morphology, immunophenotype, and genetic analysis.

KW - B lymphoblastic leukemia

KW - DNA methylation biomarker

KW - Mature B-cell neoplasms

UR - http://www.scopus.com/inward/record.url?scp=77953470572&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953470572&partnerID=8YFLogxK

M3 - Article

C2 - 20224725

AN - SCOPUS:77953470572

VL - 3

SP - 265

EP - 279

JO - International Journal of Clinical and Experimental Pathology

JF - International Journal of Clinical and Experimental Pathology

SN - 1936-2625

IS - 3

ER -